CN111658599A - 一种脂质体防晒化妆品及其制备方法 - Google Patents
一种脂质体防晒化妆品及其制备方法 Download PDFInfo
- Publication number
- CN111658599A CN111658599A CN202010689161.1A CN202010689161A CN111658599A CN 111658599 A CN111658599 A CN 111658599A CN 202010689161 A CN202010689161 A CN 202010689161A CN 111658599 A CN111658599 A CN 111658599A
- Authority
- CN
- China
- Prior art keywords
- sunscreen
- agent
- liposome
- skin
- sunscreen cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000516 sunscreening agent Substances 0.000 title claims abstract description 109
- 230000000475 sunscreen effect Effects 0.000 title claims abstract description 91
- 239000002537 cosmetic Substances 0.000 title claims abstract description 48
- 239000002502 liposome Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title description 4
- 239000000126 substance Substances 0.000 claims abstract description 26
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 15
- 229960001631 carbomer Drugs 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000000043 antiallergic agent Substances 0.000 claims abstract description 8
- 239000003755 preservative agent Substances 0.000 claims abstract description 7
- 230000002335 preservative effect Effects 0.000 claims abstract description 7
- 239000002738 chelating agent Substances 0.000 claims abstract description 5
- 239000003974 emollient agent Substances 0.000 claims abstract description 5
- 229920005862 polyol Polymers 0.000 claims abstract description 3
- 150000003077 polyols Chemical class 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- 229940068171 ethyl hexyl salicylate Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 5
- 229960000601 octocrylene Drugs 0.000 claims description 5
- 150000005846 sugar alcohols Polymers 0.000 claims description 5
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 4
- 229940036350 bisabolol Drugs 0.000 claims description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001679 octinoxate Drugs 0.000 claims description 4
- 229940101267 panthenol Drugs 0.000 claims description 4
- 235000020957 pantothenol Nutrition 0.000 claims description 4
- 239000011619 pantothenol Substances 0.000 claims description 4
- -1 polydimethylsiloxane Polymers 0.000 claims description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims description 3
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 3
- 229960000655 ensulizole Drugs 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 3
- NRTKYSGFUISGRQ-UHFFFAOYSA-N (3-heptanoyloxy-2,2-dimethylpropyl) heptanoate Chemical compound CCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCC NRTKYSGFUISGRQ-UHFFFAOYSA-N 0.000 claims description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 2
- SCVVSSZVLZQUDZ-UHFFFAOYSA-N 3-methyl-2,6-dihydro-1H-pyrimidine-2-carboxylic acid Chemical compound CN1C(NCC=C1)C(=O)O SCVVSSZVLZQUDZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 claims description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 235000013322 soy milk Nutrition 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- UUJLHYCIMQOUKC-UHFFFAOYSA-N trimethyl-[oxo(trimethylsilylperoxy)silyl]peroxysilane Chemical compound C[Si](C)(C)OO[Si](=O)OO[Si](C)(C)C UUJLHYCIMQOUKC-UHFFFAOYSA-N 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims 1
- OGEMCJNRDGZFQF-UHFFFAOYSA-N hexyl 2-benzoyl-4-(diethylamino)-3-hydroxybenzoate Chemical compound CCCCCCOC(=O)C1=CC=C(N(CC)CC)C(O)=C1C(=O)C1=CC=CC=C1 OGEMCJNRDGZFQF-UHFFFAOYSA-N 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000002045 lasting effect Effects 0.000 abstract description 3
- 210000004243 sweat Anatomy 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 38
- 238000012360 testing method Methods 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000037072 sun protection Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 3
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4966—Triazines or their condensed derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种脂质体防晒化妆品。本发明提供的化妆品是利用脂质体技术制备出的一种缓释效果好,稳定性能佳,可抗水抗汗,且肤感清爽、不油腻,作用持久的防晒化妆品;所述脂质体防晒化妆品主要由以下重量百分比组分制成:氢化卵磷脂0.5‑2%,卡波姆0.1‑1%,化学防晒剂11‑34%,皮肤调理剂1.7‑3.7%,润肤剂2‑13%,抗敏剂0.5‑3%,多元醇3‑15%,螯合剂0.01‑0.2%,成膜剂0.1‑2%,pH调节剂0.1‑1%,防腐剂0.4‑0.8%,香精0.03‑0.3%,水适量;属于化妆品技术领域。
Description
技术领域
本发明公开了一种防晒化妆品,具体地说,是一种利用脂质体技术制备的防晒化妆品, 本发明还公开了其制备方法,属于化妆品技术领域。
背景技术
当皮肤接受紫外线过度暴晒后,会损伤表皮细胞,紫外线渗入皮肤后,会产生有害的自 由基,破坏皮肤弹性纤维,导致皮肤松弛,形成皱纹,加速衰老,同时会激活酪氨酸酶,加 速黑色素合成,导致色素沉着,如黑斑、雀斑、黄褐斑等各种色斑的增多;在强烈照射下,还会造成肌肤发炎、灼伤,严重的会导致皮肤毛细血管扩张,产生红斑,还会使皮肤免疫功能下降,形成皮肤癌或癌前病变。因此,防晒在我们的日常生活中非常重要,早已成为人们护肤的必要环节。
防晒最重要的途径就是使用防晒化妆品,它能防止或减轻由于紫外线辐射而造成的皮肤 损害。而防晒剂是防晒化妆品中起防晒作用的关键成分,目前市面上的防晒剂主要分为物理 防晒剂和化学防晒剂。物理防晒剂主要有二氧化钛和氧化锌,是在皮肤表面形成覆盖层,把 照射到皮肤表面的紫外线反射或散射出去,从而减少进入皮肤中的紫外线含量,但使用时容 易堵塞毛孔,影响皮脂腺和汗腺的正常分泌,且容易脱落,影响美观。化学防晒剂常用的有 对甲氧基肉桂酸酯类、水杨酸乙基己酯及奥克立林等,这类物质能选择性吸收紫外线,分子 结构不同,选择吸收紫外线的波段也不同,防晒能力较好,但存在的安全隐患较多,比如化 学防晒剂分子量一般比较小,有透皮吸收的可能性,所以会刺激皮肤、导致皮肤过敏等,同 时部分化学防晒剂耐晒性和光稳定性不高,易被光降解,用于制备防晒化妆品,产品的安全 性和稳定性有待提高。
脂质体(liposome)是一种由脂类分子自组装形成的具有类似生物膜双分子层的超分子 结构(球形微囊),具有的双分子层结构与皮肤细胞膜结构相同,尤其是包敷了化学防晒成 分如奥克立林、甲氧基肉桂酸乙基己酯、水杨酸乙基己酯等的脂质体可消除乳状液的上述缺 点,是一种应用性能优良的乳状液,在肤感、留香、活性物质缓释、稳定性等各个层面都优 于常规的乳状液体系。利用脂质体技术制备防晒化妆品,将给广大消费者带来一种全新防晒 产品体验。但脂质体对小分子物质的缓释效果不太理想,在制备高SPF值的防晒产品时因添 加的防晒成分较多,缓释效果不理想仍会给皮肤带来一定影响,或活性成分释放较快降低其 防晒性能。因此,利用脂质体技术制备防晒化妆品的同时还需注意防晒剂的缓释问题。
发明内容
本发明的目的在于利用脂质体技术制备出一种缓释效果好,稳定性能佳,可抗水抗汗, 且肤感清爽、不油腻,作用持久的防晒化妆品。
为解决上述技术问题,本发明提供的第一个技术方案是这样的:
一种脂质体防晒化妆品,主要由以下重量百分比组分制成:氢化卵磷脂0.5-2%,卡波姆 0.1-1%,化学防晒剂11-34%,皮肤调理剂1.7-3.7%,润肤剂2-13%,抗敏剂0.5-3%,多元醇 3-15%,螯合剂0.01-0.2%,成膜剂0.1-2%,pH调节剂0.1-1%,防腐剂0.4-0.8%,香精0.03-0.3%, 水适量。
本发明中选用的氢化卵磷脂是从大豆中提取而来的,包含25%-30%的磷脂酰胆碱,是一 种具有抗炎症作用的天然乳化剂,能有效减少刺激,保湿性能好,并可作为脂质体基质,具 有较高的稳定性。
本发明中选用的卡波姆是一种由丙烯酸或丙烯酸酯与烯丙基醚化学交联形成的聚合物, 可水化形成凝胶,在缓、控释制剂中,作为水凝胶骨架材料,通过形成的凝胶层可控制活性 成分的释放。
进一步的,上述脂质体防晒化妆品,所述化学防晒剂包括油溶性防晒成分和水溶性防晒 成分,所述油溶性防晒成分选自甲氧基肉桂酸乙基己酯//丁羟甲苯、奥克立林、二乙氨羟苯甲 酰基苯甲酸己酯、乙基己基三嗪酮、水杨酸乙基己酯、双-乙基己氧苯酚甲氧苯基三嗪中的任 意四种或以上组合,所述水溶性防晒成分选自亚甲基双-苯并三唑基四甲基丁基酚、苯基苯并 咪唑磺酸中的任意一种或组合。
本发明中选用的油溶性防晒成分中甲氧基肉桂酸乙基己酯//丁羟甲苯采购自广州市百好 博有限公司,是应用最为广泛的UVB吸收剂,能有效防止280-310nm的紫外线,且吸收率 高,对皮肤无刺激,安全性好;奥克立林能吸收UVB和少量UVA,有助于其他油溶固体防 晒剂的溶解,对光、热稳定性较好;二乙氨羟苯甲酰基苯甲酸己酯是市场唯一光稳定的UVA 滤光剂,与UVB过滤剂复配能提高防晒产品的功效,对皮肤起极好的保护和修复作用;乙基 己基三嗪酮是近年发展起来的一类新型紫外线吸收剂,它具有较大的分子结构和很高的紫外 线吸收效率,具有广谱防晒效果,既防UVB段紫外线,又防UVA段紫外线,且光稳定性强、 耐水性强,对皮肤的角质蛋白有较好的亲和力;水杨酸乙基己酯是一种UVB吸收剂,吸收率 低,该成分常与其他防晒剂为伍使用;双-乙基己氧苯酚甲氧苯基三嗪是一种广谱防晒剂,可 防护一部分的UVB以及全部的UVA,其分子量大,不易被皮肤吸收,稳定性强,还可做为 其他化学防晒剂的稳定剂,与其他防晒剂的相溶性强。
本发明中选用的水溶性防晒成分中亚甲基双-苯并三唑基四甲基丁基酚对于UVA和UVB 都具有防护效果,光稳定性好;苯基苯并咪唑磺酸一种紫外线UVB防晒剂,也能吸收很小部 分的UVA波段。
进一步的,上述脂质体防晒化妆品,所述皮肤调理剂选自硅石、滑石粉、红没药醇、生 育酚乙酸酯、四氢甲基嘧啶羧酸中的任意三种或以上组合;所述润肤剂选自异十二烷、异十 六烷、聚二甲基硅氧烷、新戊二醇二庚酸酯中的任意两种或以上组合。
进一步的,上述脂质体防晒化妆品,所述抗敏剂选自尿囊素、泛醇、水//乳酸杆菌/豆浆 发酵产物滤液//丁二醇//1,2-戊二醇中的任意两种或以上组合;所述多元醇选自甘油、丙二醇、 丁二醇、1,3-丙二醇中的任意两种或以上组合。
本发明中选用的水//乳酸杆菌/豆浆发酵产物滤液//丁二醇//1,2-戊二醇采购于广州仙婷贸 易有限公司,该原料对皮肤有保湿、舒缓、修护、抗过敏的功效,可抵御紫外线对皮肤的伤 害,对敏感脆弱皮肤进行晒后修护,同时可减轻化学防晒成分对皮肤的刺激。
进一步的,上述脂质体防晒化妆品,所述螯合剂选自EDTA二钠、EDTA四钠中的任意一种或组合;所述成膜剂选自糊精异硬脂酸酯、三甲基硅烷氧基硅酸酯中的任意一种或组合。
进一步的,上述脂质体防晒化妆品,所述pH调节剂选自三乙醇胺、精氨酸中的任意一 种或组合;所述防腐剂选自氯苯甘醚、苯氧乙醇、乙基己基甘油、o-伞花烃-5-醇中的任意两 种或以上组合。
进一步的,上述脂质体防晒化妆品,所述氢化卵磷脂和卡波姆的质量比为4:1。
此外,本发明还可以添加一些稳定助剂如癸基葡糖苷、黄原胶等,添加量可以为防晒化 妆品总质量的0.01-0.1%。
本发明提供的第二个技术方案是这样的:
上述脂质体防晒化妆品,主要由以下方法制备得到:
(1)将氢化卵磷脂,多元醇中的甘油和/或丙二醇加热至70-80℃,在2000-3000r/min超 高速条件下均质3min,待用;
(2)将卡波姆,抗敏剂中的尿囊素和/或泛醇,皮肤调理剂中的硅石和/或滑石粉以及水 加入水相锅中,加热至80-90℃后加入步骤(1)的混合相,搅拌均匀;
(3)将油溶性的化学防晒成分,润肤剂,成膜剂,皮肤调理剂中的红没药醇和/或生育 酚乙酸酯加入油相锅中,升温至75-85℃,将其缓慢抽入步骤(2)的混合相中在1500r/min 高速条件下均质4-6min,搅拌均匀,保温30min抽真空消泡降温;
(4)将步骤(3)的混合相降温至45℃时,加入水溶性化学防晒成分、防腐剂、pH调节剂、剩余的抗敏剂和皮肤调理剂搅拌3-5min;
(5)将步骤(4)的混合相降温至40℃时,加入香精搅拌均匀,对版合格后200-300目过滤出料即可。
本发明制备的脂质体防晒化妆品为淡黄色乳霜,pH值为5.5-7.5,形成的脂质体为单室脂 质体,对活性成分的包封率及缓释性能良好,能减小高浓度化学防晒成分对皮肤的刺激,同 时实现活性成分的持久释放,且稳定性佳。
与现有技术相比,本发明提供的技术方案具有如下技术优点:
1、本发明采用氢化卵磷脂作为脂质体的基质,将其用多元醇分散并在高温和高剪切速率 下均质,完成破壁重新组合形成脂质体双分子层结构,再包裹防晒活性成分形成最终产品, 该制备方法简单,形成的脂质体在高温、低温等条件下稳定性很好。
2、本发明防晒产品不含物理防晒剂,质感爽滑,不粘腻,易涂抹,不泛白,采用多种油 溶性化学防晒成分和水溶性化学防晒成分共同作用,对不同波段的紫外线均有吸收作用,起 到广谱防晒效果,屏蔽紫外线,减轻因日晒引起的皮肤损伤,黑色素沉着及皮肤老化等现象。 尤其当油溶性防晒成分和水溶性防晒成分共存时,产品的防晒效果更好。且本发明以氢化卵 磷脂模拟细胞膜结构包裹油溶性防晒成分,形成稳定规则的乳化液滴,因相似相容原理,乳 化液滴具有皮肤角质层相似结构,从而增加其贴肤性,铺展性,锁住有效成分,减少防晒剂 迁移扩散,对防晒值产生增益效果,再加上脂质体的特性,使产品同时具有抗水抗汗性能, 使用后肤感清爽、不厚重。
3、本发明中采用的卡波姆可控制活性成分的释放,其与氢化卵磷脂形成的脂质体共同作 用,尤其在特定比例下,增加其对化学、光、热、氧化等条件的稳定性,增加对活性成分的 包封率,解决分子量较小的防晒成分缓释效果不理想的问题,可以减少过敏反应,增加防晒 SPF值。
具体实施方式
下面结合具体实施例对本发明的技术方案做进一步的详述,但所描述的实施例仅仅是本 发明的一部分实施例,而不是全部实施例,其他的任何未背离本发明的精神实质与原理下所 作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围 之内。对于未特别注明的工艺参数或者条件,可参照常规技术进行。本发明所用的原料可通 过自制获得或商业渠道购买。
表1为本发明技术方案中的部分实施例,但本发明的实施方式不限于此。其中,各实施 例中原料含量均是以wt%表示。
表1本发明提供的实施例1-5
实施例1-5脂质体防晒化妆品的制备方法如下:
(1)将A1相物料加热至70-80℃(优选70℃),在2000-3000r/min(优选2000r/min)超高速条件下均质3min,待用;
(2)将A相物料加入水相锅中,加热至80-90℃(优选90℃)后加入步骤(1)的混合相,搅拌均匀;
(3)将B相物料加入油相锅中,升温至75-85℃(优选80℃),将其缓慢抽入步骤(2)的混合相中在1500r/min高速条件下均质4-6min(优选5min),搅拌均匀,保温30分钟抽真空消泡降温;
(4)将步骤(3)的混合相降温至45℃时,加入C相物料搅拌3-5min(优选4min);
(5)将步骤(4)的混合相降温至40℃时,加入D相物料搅拌均匀,对版合格后200-300 目(优选300目)过滤出料即可。
另外,针对本申请的发明点,本发明还设置了对比例。
表2本发明提供的对比例1-3
其中,对比例1与实施例1对比,将氢化卵磷脂用等量的菊粉月桂基氨基甲酸酯替换, 其他成分不变;对比例2与实施例1对比,将卡波姆用等量的丙烯酰二甲基牛磺酸铵/VP共 聚物替换,其他成分不变;对比例3与实施例1对比,不含水溶性的化学防晒成分,但防晒成分的总量相同,其他成分不变。
对比例1-3防晒化妆品的制备方法与实施例1-5的制备方法相同。
为了更好的说明本发明的优点,下面给出本发明提供的脂质体防晒化妆品的功效试验:
测试1:稳定性试验
(1)测试样品:实施例1-5制备的防晒化妆品。
(2)测试方法:将测试样品在高温48℃、低温-15℃、D65光源三个条件下进行测试,测试周期为1个月,每个测试条件下放置5个样品,每隔一周查看稳定性情况。观察各组样品是否有分层、结晶、变色、变味等现象。
(3)测试结果:经过测试,实施例1-5制备的脂质体防晒化妆品,在高温、低温或光照 等测试条件下,均未出现分层、析出颗粒、结晶现象,也未出现变色、变味等其他异常现象。 说明本发明制备的脂质体防晒化妆品稳定性良好,能充分满足不同环境下的长期使用和高低 温运输。
测试2:皮肤刺激性测试
(1)测试样品:实施例1-5制备的防晒化妆品。
(2)测试方法:选取30名志愿者,受试者应符合志愿入选标准,无过敏性皮炎史,且前一个月也未使用刺激性产品。
取实施例1-5制备的化妆品约0.020~0.025ml涂于斑试器(北京科普仪器厂)小室中, 外用专用胶带贴敷于受试者背部,24小时后除去斑试器,如有剩余产品用湿润的纸巾轻轻擦 去,分别于0.5小时,24小时,48小时,按《化妆品安全技术规范》(2015)中皮肤反应分 级标准记录其结果。鉴定标准见表3。
表3鉴定标准
等级 | 鉴定标准 |
0 | 无刺激、无红斑 |
1 | 轻度红斑 |
2 | 红斑 |
3 | 红斑、丘疹、水泡 |
4 | 严重附浮肿、大泡 |
由封闭型斑贴测试结果可知,30名受试者在0.5小时,24小时,48小时对实施例1-5制 得的脂质体防晒化妆品均未表现出任何不良反应,没有出现红斑、烧灼感、瘙痒等症状。说 明本发明防晒化妆品使用安全,对皮肤无刺激。
测试3:SPF(防晒指数)值测试
SPF为日光防护系数,定义为引起被防晒化妆品防护的皮肤产生红斑所需的MED(最小 红斑量)与未被防护的皮肤产生红斑所需的MED之比,可用以评价化妆品的防晒能力,SPF 值越大,防晒效果越好。
(1)测试样品:实施例1-5,对比例1-3制备的防晒化妆品。
(2)测试方法:采用SPF-290型仪器测试法来测定样品的SPF值。先用仪器本身附带的滤片及标准品进行点检测试,一切正常后再进行样品测试。先测定空白膜的本底曲线,然后用点样器在3M胶带上均匀点加样品,用带有乳胶手指套的手指涂抹,使膜表面的样品以2μL/cm2分布。然后将涂抹后的样品板放在37℃的恒温干燥箱中干燥,用SPF-290分析仪在透明膜上随机选取6个点测试,最后利用工作站处理数据,得到相应的SPF值。测试结果见表4。
表4SPF值测试结果
从表4的实验结果可以看出,随着配方中防晒成分含量的增大,防晒产品的SPF值也随 之增大,且实施例的防晒效果明显优于对比例。由实施例1和对比例1、2对比可知,氢化卵 磷脂形成的脂质体和卡波姆形成的凝胶层共同作用,可进一步减少防晒剂迁移扩散,对分子 量小的化学防晒剂的缓释效果更佳,对防晒值产生增益效果;由实施例4和实施例5对比可 知,当氢化卵磷脂和卡波姆在特定比例下复配时,具有更好、更持久的防晒效果;由实施例 1和对比例3对比可知,当配方中油溶性防晒成分和水溶性防晒成分共存时,产品的防晒效 果更好。
测试4:肤感测试
(1)测试样品:实施例1,对比例1、2制备的防晒化妆品。
(2)测试方法:参照国家制定的标准GB/T13868-2009《感官分析-建立感官分析实验室 的一般导则》,建立实验室感官分析标准,参考上述标准,对防晒产品进行评价实验。选择 其中的铺展性、厚重感、吸收性、粘感评价指标进行实验。选择20位健康状况良好的志愿者, 年龄在20岁-40岁之间,志愿者应具备正确的感觉辨别能力。吸取一定量的测试样品(约 2mg/cm2)置于志愿者的手臂内侧,志愿者用另一只手手指进行涂布,涂布呈2.5cm的圆形区 域,以每秒钟两圈的速度进行涂布,在此过程中同时进行感官评测,进行评分取平均值,其 结果如表5所示。
(3)评分标准:各项指标的最高分为10分,9-10分表示非常满意;8-9分是相对满意; 6-8分是可以接受;6分以下为不可接受。
表5肤感测试结果
由表5的结果可看出,与对比例相比,本发明的防晒化妆品具有良好的铺展性、吸收性, 且不油腻、不粘肤,说明使用本发明产品肤感清爽,更有利于皮肤吸收,肤感更佳。
Claims (8)
1.一种脂质体防晒化妆品,其特征在于,主要由以下重量百分比组分制成:氢化卵磷脂0.5-2%,卡波姆0.1-1%,化学防晒剂11-34%,皮肤调理剂1.7-3.7%,润肤剂2-13%,抗敏剂0.5-3%,多元醇3-15%,螯合剂0.01-0.2%,成膜剂0.1-2%,pH调节剂0.1-1%,防腐剂0.4-0.8%,香精0.03-0.3%,水适量。
2.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述化学防晒剂包括油溶性防晒成分和水溶性防晒成分,所述油溶性防晒成分选自甲氧基肉桂酸乙基己酯//丁羟甲苯、奥克立林、二乙氨羟苯甲酰基苯甲酸己酯、乙基己基三嗪酮、水杨酸乙基己酯、双-乙基己氧苯酚甲氧苯基三嗪中的任意四种或以上组合,所述水溶性防晒成分选自亚甲基双-苯并三唑基四甲基丁基酚、苯基苯并咪唑磺酸中的任意一种或组合。
3.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述皮肤调理剂选自硅石、滑石粉、红没药醇、生育酚乙酸酯、四氢甲基嘧啶羧酸中的任意三种或以上组合;所述润肤剂选自异十二烷、异十六烷、聚二甲基硅氧烷、新戊二醇二庚酸酯中的任意两种或以上组合。
4.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述抗敏剂选自尿囊素、泛醇、水//乳酸杆菌/豆浆发酵产物滤液//丁二醇//1,2-戊二醇中的任意两种或以上组合;所述多元醇选自甘油、丙二醇、丁二醇、1,3-丙二醇中的任意两种或以上组合。
5.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述螯合剂选自EDTA二钠、EDTA四钠中的任意一种或组合;所述成膜剂选自糊精异硬脂酸酯、三甲基硅烷氧基硅酸酯中的任意一种或组合。
6.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述pH调节剂选自三乙醇胺、精氨酸中的任意一种或组合;所述防腐剂选自氯苯甘醚、苯氧乙醇、乙基己基甘油、o-伞花烃-5-醇中的任意两种或以上组合。
7.根据权利要求1所述的一种脂质体防晒化妆品,其特征在于,所述氢化卵磷脂和卡波姆的质量比为4:1。
8.根据权利要求1-7任一所述的脂质体防晒化妆品,其特征在于,主要由以下方法制备得到:
(1)将氢化卵磷脂,多元醇中的甘油和/或丙二醇加热至70-80℃,在2000-3000r/min超高速条件下均质3min,待用;
(2)将卡波姆,抗敏剂中的尿囊素和/或泛醇,皮肤调理剂中的硅石和/或滑石粉以及水加入水相锅中,加热至80-90℃后加入步骤(1)的混合相,搅拌均匀;
(3)将油溶性的化学防晒成分,润肤剂,成膜剂,皮肤调理剂中的红没药醇和/或生育酚乙酸酯加入油相锅中,升温至75-85℃,将其缓慢抽入步骤(2)的混合相中在1500r/min高速条件下均质4-6min,搅拌均匀,保温30min抽真空消泡降温;
(4)将步骤(3)的混合相降温至45℃时,加入水溶性化学防晒成分、防腐剂、pH调节剂、剩余的抗敏剂和皮肤调理剂搅拌3-5min;
(5)将步骤(4)的混合相降温至40℃时,加入香精搅拌均匀,对版合格后200-300目过滤出料即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010689161.1A CN111658599A (zh) | 2020-07-17 | 2020-07-17 | 一种脂质体防晒化妆品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010689161.1A CN111658599A (zh) | 2020-07-17 | 2020-07-17 | 一种脂质体防晒化妆品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111658599A true CN111658599A (zh) | 2020-09-15 |
Family
ID=72392754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010689161.1A Pending CN111658599A (zh) | 2020-07-17 | 2020-07-17 | 一种脂质体防晒化妆品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111658599A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894410A (zh) * | 2022-11-22 | 2023-04-04 | 无锡凯高贸易有限公司 | 一种防晒化合物、防晒化妆品及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030215A1 (en) * | 1997-01-13 | 1998-07-16 | Cilag Ag | Liposome-based topical tretinoin formulation |
KR20120138877A (ko) * | 2011-06-16 | 2012-12-27 | 유우영 | 자외선 차단 화장료 조성물 및 그 제조방법 |
CN107157788A (zh) * | 2017-05-05 | 2017-09-15 | 海南京润珍珠生物技术股份有限公司 | 一种添加甲氧基肉桂酸乙基己酯脂质体包裹物的防晒霜 |
CN109820738A (zh) * | 2019-03-29 | 2019-05-31 | 广东芭薇生物科技股份有限公司 | 一种高倍水包油型防晒化妆品 |
CN111000761A (zh) * | 2019-12-23 | 2020-04-14 | 苏州绿叶日用品有限公司 | 一种含水溶性组分的防晒棒及其制备方法 |
-
2020
- 2020-07-17 CN CN202010689161.1A patent/CN111658599A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030215A1 (en) * | 1997-01-13 | 1998-07-16 | Cilag Ag | Liposome-based topical tretinoin formulation |
KR20120138877A (ko) * | 2011-06-16 | 2012-12-27 | 유우영 | 자외선 차단 화장료 조성물 및 그 제조방법 |
CN107157788A (zh) * | 2017-05-05 | 2017-09-15 | 海南京润珍珠生物技术股份有限公司 | 一种添加甲氧基肉桂酸乙基己酯脂质体包裹物的防晒霜 |
CN109820738A (zh) * | 2019-03-29 | 2019-05-31 | 广东芭薇生物科技股份有限公司 | 一种高倍水包油型防晒化妆品 |
CN111000761A (zh) * | 2019-12-23 | 2020-04-14 | 苏州绿叶日用品有限公司 | 一种含水溶性组分的防晒棒及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115894410A (zh) * | 2022-11-22 | 2023-04-04 | 无锡凯高贸易有限公司 | 一种防晒化合物、防晒化妆品及其制备方法 |
CN115894410B (zh) * | 2022-11-22 | 2024-05-14 | 百特威(上海)化妆品有限公司 | 一种防晒化合物、防晒化妆品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110339115B (zh) | 一种修护精华液及其制备方法 | |
CN111700811B (zh) | 一种美白防晒双功能防晒喷雾及其制备方法 | |
CN109820738B (zh) | 一种高倍水包油型防晒化妆品 | |
CN109833214B (zh) | 一种温和水包油型pickering防晒护肤品及其制备方法 | |
CN109908004B (zh) | 一种多重乳液防晒化妆品及其制备方法 | |
CN112842960A (zh) | 一种同时具有抗紫外线、美白、抗衰老的化妆品组合物 | |
CN110292543B (zh) | 一种替代紫外线吸收剂的生物组合物及其应用 | |
CN113041172B (zh) | 用于肌肤屏障修护的皮脂膜仿生组合物及其应用和化妆品 | |
CN112263493B (zh) | 一种防晒组合物、包含其的防晒凝露及其制备方法 | |
CN112516022B (zh) | 一种防晒露及其制备方法 | |
CN111658599A (zh) | 一种脂质体防晒化妆品及其制备方法 | |
EP1648391A1 (en) | Method and preparation for reducing sunburn cell formation in skin | |
CN113995693A (zh) | 一种具有抗炎功效脂质体的精华液组合物及其制备方法和应用 | |
CN116139064B (zh) | 一种防晒增效组合物及其应用和化妆品 | |
CN112603875A (zh) | 一种防晒组合物及其应用 | |
CN112220693A (zh) | 含挪威云杉叶提取物的晒后修护固态喷雾及其制备方法 | |
KR20150106244A (ko) | 자외선 차단 및 보습용 화장품 조성물 | |
CN115300417B (zh) | 一种适用于儿童和敏感肌的防晒霜及其制备方法 | |
CN115282106A (zh) | 一种含有余甘子提取物的防晒乳制剂及其制备方法 | |
CN115969749A (zh) | 一种防晒组合物及其制备方法 | |
CN115670993A (zh) | 一种具有修护舒缓功效的超分子组合物的制备方法及其应用 | |
CN113749972B (zh) | 一种具有抗皱效果的组合物及其在化妆品中的应用 | |
CN115040463A (zh) | 一种抗皱美白组合物 | |
CN115024994A (zh) | 一种高安全型防晒组合物及其制备方法与应用 | |
CN111434326A (zh) | 隔离防护霜及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200915 |
|
RJ01 | Rejection of invention patent application after publication |